Needham & Company reiterates a 'Buy' rating on ISIS Pharmaceuticals (Nasdaq: ISIS), price target $22.

Needham analyst says, "Yesterday, ISIS ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE